Construction of chimeric IL-21 recombinant oncolytic influenza virus and mechanisms for its antitumor efficacy against hepatocellular carcinoma

Objective To rescue a recombinant oncolytic influenza virus chimeric with IL-21 and evaluate its inhibitory effects and safety against hepatocellular carcinoma (HCC) both in vitro and in vivo, and to explore the mechanism by which this virus enhances antitumor effects when combined with anti-program...

Full description

Saved in:
Bibliographic Details
Main Authors: CAO Rui, ZENG Guineng, TIAN Yuying
Format: Article
Language:zho
Published: Editorial Office of Journal of Army Medical University 2024-12-01
Series:陆军军医大学学报
Subjects:
Online Access:https://aammt.tmmu.edu.cn/html/202407051.htm
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846101674630840320
author CAO Rui
ZENG Guineng
TIAN Yuying
TIAN Yuying
author_facet CAO Rui
ZENG Guineng
TIAN Yuying
TIAN Yuying
author_sort CAO Rui
collection DOAJ
description Objective To rescue a recombinant oncolytic influenza virus chimeric with IL-21 and evaluate its inhibitory effects and safety against hepatocellular carcinoma (HCC) both in vitro and in vivo, and to explore the mechanism by which this virus enhances antitumor effects when combined with anti-programmed cell death protein 1(anti-PD-1) antibody. Methods The IL-21 gene fragment was inserted into the nonstructural protein (NS) sequence of the influenza virus PR8 using reverse genetics (RG) technology to rescue the recombinant oncolytic influenza virus rOV-IL-21-NS.The virus titer and virulence were determined using the 50% tissue culture infectious dose (TCID50) and hemagglutination assays.The successful insertion of the exogenous gene into the NS sequence was verified using RT-qPCR, gel electrophoresis, and sequencing analysis.Viral morphology and size were observed with transmission electron microscopy.The impact of the virus on the viability of hepatocellular carcinoma cells was assessed with CCK-8 assay.A subcutaneous tumor model of HCC was established in 45 female C57BL/6 mice (8 weeks old, weighing 16~20 g), and then the mice were randomly assigned into PBS, PR8, anti-PD-1, rOV-IL-21-NS, and the rOV-IL-21-NS+anti-PD-1 treatment groups, with 9 mice in each group, to evaluate the anti-tumor effects of monotherapy versus combination therapy.Flow cytometry was conducted to assess the regulatory effects of monotherapy and combination therapy on the tumor immune microenvironment. Results RG technology successfully rescued the recombinant oncolytic influenza virus rOV-IL-21-NS.Sequencing confirmed the successful insertion of IL-21 into the target sequence, and the obtained virus could be stably propagated, with its sixth passage reaching a hemagglutination titer of 211, and a viral titer of 6 Log10(TCID50/mL).Oncolytic virus rOV-IL-21-NS, at a multiplicity of infection (MOI) of 3, selectively reduced the viability of HCC cells without significantly affecting normal liver cells.Compared to the control group, the combination of rOV-IL-21-NS and anti-PD-1 antibodies significantly inhibited tumor growth (P < 0.001) and increased the proportions of CD4+ T and CD8+ T cells in the spleen tissue of the mouse model of subcutaneous HCC tumor (P < 0.001). Conclusion The recombinant oncolytic influenza virus rOV-IL-21-NS chimeric with IL-21 can effectively and safely exert targeted killing to HCC cells, enhance T cell activation by synergizing with anti-PD-1 antibodies, and improve the immune microenvironment.
format Article
id doaj-art-0fbabbbaae6e45d99cf2cd5817ba69b1
institution Kabale University
issn 2097-0927
language zho
publishDate 2024-12-01
publisher Editorial Office of Journal of Army Medical University
record_format Article
series 陆军军医大学学报
spelling doaj-art-0fbabbbaae6e45d99cf2cd5817ba69b12024-12-29T00:27:03ZzhoEditorial Office of Journal of Army Medical University陆军军医大学学报2097-09272024-12-0146242736274410.16016/j.2097-0927.202407051Construction of chimeric IL-21 recombinant oncolytic influenza virus and mechanisms for its antitumor efficacy against hepatocellular carcinomaCAO Rui0 ZENG Guineng1TIAN Yuying2TIAN Yuying3School of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 010110Faculty of Hepato-Biliary-Pancreatic Surgery, First Medical Center, Chinese PLA General Hospital, Beijing, 100853, ChinaSchool of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 010110 Faculty of Hepato-Biliary-Pancreatic Surgery, First Medical Center, Chinese PLA General Hospital, Beijing, 100853, ChinaObjective To rescue a recombinant oncolytic influenza virus chimeric with IL-21 and evaluate its inhibitory effects and safety against hepatocellular carcinoma (HCC) both in vitro and in vivo, and to explore the mechanism by which this virus enhances antitumor effects when combined with anti-programmed cell death protein 1(anti-PD-1) antibody. Methods The IL-21 gene fragment was inserted into the nonstructural protein (NS) sequence of the influenza virus PR8 using reverse genetics (RG) technology to rescue the recombinant oncolytic influenza virus rOV-IL-21-NS.The virus titer and virulence were determined using the 50% tissue culture infectious dose (TCID50) and hemagglutination assays.The successful insertion of the exogenous gene into the NS sequence was verified using RT-qPCR, gel electrophoresis, and sequencing analysis.Viral morphology and size were observed with transmission electron microscopy.The impact of the virus on the viability of hepatocellular carcinoma cells was assessed with CCK-8 assay.A subcutaneous tumor model of HCC was established in 45 female C57BL/6 mice (8 weeks old, weighing 16~20 g), and then the mice were randomly assigned into PBS, PR8, anti-PD-1, rOV-IL-21-NS, and the rOV-IL-21-NS+anti-PD-1 treatment groups, with 9 mice in each group, to evaluate the anti-tumor effects of monotherapy versus combination therapy.Flow cytometry was conducted to assess the regulatory effects of monotherapy and combination therapy on the tumor immune microenvironment. Results RG technology successfully rescued the recombinant oncolytic influenza virus rOV-IL-21-NS.Sequencing confirmed the successful insertion of IL-21 into the target sequence, and the obtained virus could be stably propagated, with its sixth passage reaching a hemagglutination titer of 211, and a viral titer of 6 Log10(TCID50/mL).Oncolytic virus rOV-IL-21-NS, at a multiplicity of infection (MOI) of 3, selectively reduced the viability of HCC cells without significantly affecting normal liver cells.Compared to the control group, the combination of rOV-IL-21-NS and anti-PD-1 antibodies significantly inhibited tumor growth (P < 0.001) and increased the proportions of CD4+ T and CD8+ T cells in the spleen tissue of the mouse model of subcutaneous HCC tumor (P < 0.001). Conclusion The recombinant oncolytic influenza virus rOV-IL-21-NS chimeric with IL-21 can effectively and safely exert targeted killing to HCC cells, enhance T cell activation by synergizing with anti-PD-1 antibodies, and improve the immune microenvironment. https://aammt.tmmu.edu.cn/html/202407051.htmoncolytic virusreverse genetic technologycombination therapyil-21anti-programmed cell death protein 1 antibodyhepatocellular carcinoma
spellingShingle CAO Rui
ZENG Guineng
TIAN Yuying
TIAN Yuying
Construction of chimeric IL-21 recombinant oncolytic influenza virus and mechanisms for its antitumor efficacy against hepatocellular carcinoma
陆军军医大学学报
oncolytic virus
reverse genetic technology
combination therapy
il-21
anti-programmed cell death protein 1 antibody
hepatocellular carcinoma
title Construction of chimeric IL-21 recombinant oncolytic influenza virus and mechanisms for its antitumor efficacy against hepatocellular carcinoma
title_full Construction of chimeric IL-21 recombinant oncolytic influenza virus and mechanisms for its antitumor efficacy against hepatocellular carcinoma
title_fullStr Construction of chimeric IL-21 recombinant oncolytic influenza virus and mechanisms for its antitumor efficacy against hepatocellular carcinoma
title_full_unstemmed Construction of chimeric IL-21 recombinant oncolytic influenza virus and mechanisms for its antitumor efficacy against hepatocellular carcinoma
title_short Construction of chimeric IL-21 recombinant oncolytic influenza virus and mechanisms for its antitumor efficacy against hepatocellular carcinoma
title_sort construction of chimeric il 21 recombinant oncolytic influenza virus and mechanisms for its antitumor efficacy against hepatocellular carcinoma
topic oncolytic virus
reverse genetic technology
combination therapy
il-21
anti-programmed cell death protein 1 antibody
hepatocellular carcinoma
url https://aammt.tmmu.edu.cn/html/202407051.htm
work_keys_str_mv AT caorui constructionofchimericil21recombinantoncolyticinfluenzavirusandmechanismsforitsantitumorefficacyagainsthepatocellularcarcinoma
AT zengguineng constructionofchimericil21recombinantoncolyticinfluenzavirusandmechanismsforitsantitumorefficacyagainsthepatocellularcarcinoma
AT tianyuying constructionofchimericil21recombinantoncolyticinfluenzavirusandmechanismsforitsantitumorefficacyagainsthepatocellularcarcinoma
AT tianyuying constructionofchimericil21recombinantoncolyticinfluenzavirusandmechanismsforitsantitumorefficacyagainsthepatocellularcarcinoma